Local view for "http://purl.org/linkedpolitics/eu/plenary/2012-10-23-Speech-2-553-250"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2012-10-23"^^xsd:date2
dcterms:Is Part Of	lp_eu:Explanations of vote2
dcterms:Language	"ro"^^xsd:language2
lpv:document identification number	"en.20121023.45.2-553-250"2
lpv:hasSubsequent	lp_eu:2012-10-23-Speech-2-553-3122
lpv:speaker	lp:Minodora Cliveti2
lpv:spokenAs	substitute; Delegation to the Euronest Parliamentary Assembly (2012-05-21--2014-06-30)3 member; EMPL (2012-05-23--2014-06-30)3 member; S&D (2012-05-18--2014-06-30)3 substitute; Delegation to the EU-Armenia, EU-Azerbaijan and EU-Georgia Parliamentary Cooperation Committees (2012-05-21--2014-06-30)3 substitute; ENVI (2012-05-21--2014-06-30)3 unknown; Partidul Social Democrat (2012-05-18--2014-06-30)3 member; Delegation to the EU-Moldova Parliamentary Cooperation Committee (2012-05-23--2014-06-30)3 substitute; Delegation for relations with Canada (2012-06-20--2014-06-30)3 substitute; FEMM (2012-05-21--2014-06-30)3
lpv:translated text	". The additional Protocol to the Euro-Mediterranean Agreement establishing an Association between the European Communities and their Member States, and the State of Israel on an Agreement between the European Community and the state of Israel on Conformity Assessment and Acceptance of Industrial Products (ACAA) provides EU exporters with an optional and mutual single testing and certification mechanism. This is applicable to sectors that are already aligned and means that these products will be able to access the Israeli market without further certification procedures and assessments. I voted for this agreement, which aims to improve EU-Israel relations. It is a mutually beneficial agreement for both Europe and Israel, which will experience increased trade, especially in the pharmaceutical field, and better trade conditions such as cost reductions for European patients, faster market access, a greater variety of pharmaceutical products, and better controls of pharmaceutical products from outside the EU. The arguments against this agreement were neither convincing nor consistent and were mainly political and economic. Moreover, consideration has not been given to the very likely EU market losses (mutual arrangements can mean Israeli sanctions) should the ACAA be rejected."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph